Trials / Completed
CompletedNCT05050318
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
Collection of Serum Samples From Children 6 Months to < 9 Years of Age Who Received Fluzone® Quadrivalent and Adults ≥ 65 Years of Age Who Received Fluzone® High-Dose Quadrivalent, Influenza Vaccines, 2021-2022 Formulations
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Sanofi Pasteur, a Sanofi Company · Industry
- Sex
- All
- Age
- 6 Months
- Healthy volunteers
- Accepted
Summary
This was a phase IV, multi-center, open-label study. The study collected serum samples from children 6 months to less than (\<) 9 years of age who received Fluzone Quadrivalent vaccine and adults greater than or equal to (\>=) 65 years of age who received Fluzone High-Dose Quadrivalent vaccine for submission to CBER to aid in the influenza vaccine strain selection process.
Detailed description
Study duration per participant was approximately 28 days for participants with 6 months to \< 9 years of age, and 21 days for participants \>= 65 years of age, including 1 to 3 visits (1 or 2 vaccination visits) and 1 or 2 telephone calls, depending on study Group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation | Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM) |
| BIOLOGICAL | Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation | Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM) |
Timeline
- Start date
- 2021-09-08
- Primary completion
- 2021-11-10
- Completion
- 2021-11-10
- First posted
- 2021-09-20
- Last updated
- 2025-09-12
- Results posted
- 2022-09-14
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05050318. Inclusion in this directory is not an endorsement.